Autolus Therapeutics/$AUTL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Autolus Therapeutics
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
Ticker
$AUTL
Sector
Primary listing
Employees
649
Headquarters
Website
AUTL Metrics
BasicAdvanced
$389M
-
-$0.87
1.90
-
Price and volume
Market cap
$389M
Beta
1.9
52-week high
$2.70
52-week low
$1.11
Average daily volume
3.1M
Financial strength
Current ratio
8.174
Quick ratio
7.819
Long term debt to equity
88.289
Total debt to equity
89.235
Interest coverage (TTM)
-15.62%
Profitability
EBITDA (TTM)
-261.311
Gross margin (TTM)
-296.40%
Net profit margin (TTM)
-760.94%
Operating margin (TTM)
-901.89%
Effective tax rate (TTM)
-1.84%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
-21.43%
Return on equity (TTM)
-52.11%
Valuation
Price to revenue (TTM)
12.714
Price to book
1.12
Price to tangible book (TTM)
1.16
Price to free cash flow (TTM)
-1.22
Free cash flow yield (TTM)
-81.98%
Free cash flow per share (TTM)
-1.197
Growth
Revenue change (TTM)
185.17%
Earnings per share change (TTM)
-19.86%
3-year revenue growth (CAGR)
271.89%
3-year earnings per share growth (CAGR)
-21.95%
Bulls say / Bears say
On April 16, 2025, the FDA accepted Autolus’s IND application for AUTO1 in adult acute lymphoblastic leukemia, marking a key regulatory milestone that advances the company’s lead program toward pivotal clinical trials (Reuters)
Autolus projects that COVID-19 will have minimal impact on its AUTO1-AL1 clinical study, demonstrating the resilience of its trial timelines amid ongoing pandemic-related uncertainties (Reuters)
The company has maintained uninterrupted manufacturing operations at its Cell and Gene Therapy Catapult facility in Stevenage, UK, bolstering supply chain stability for its next-generation T-cell therapies (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Autolus Therapeutics stock?
Autolus Therapeutics (AUTL) has a market cap of $389M as of September 08, 2025.
What is the P/E ratio for Autolus Therapeutics stock?
The price to earnings (P/E) ratio for Autolus Therapeutics (AUTL) stock is 0 as of September 08, 2025.
Does Autolus Therapeutics stock pay dividends?
No, Autolus Therapeutics (AUTL) stock does not pay dividends to its shareholders as of September 08, 2025.
When is the next Autolus Therapeutics dividend payment date?
Autolus Therapeutics (AUTL) stock does not pay dividends to its shareholders.
What is the beta indicator for Autolus Therapeutics?
Autolus Therapeutics (AUTL) has a beta rating of 1.9. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.